Viveve Medical, which is commercializing a non-invasive medical system that reverses vaginal laxity, filed on Tuesday with the SEC to raise up to $11.5 million in an initial public offering ($10 million before the underwriter overallotment).
The Sunnyvale, CA-based company was founded in 2005 and booked $1.5 million in sales for the 12 months ended December 31, 2015. It plans to list on the Nasdaq under the symbol VIVE. Ladenburg Thalmann & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.
